Corvus Pharmaceuticals suffered lately, especially after it announced in December 2024 its early AD data. Check out why I ...

Corvus Pharmaceuticals has faced volatility due to mixed clinical data and given the current valuation and market ...

“The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of ...

Corvus Pharmaceuticals reported positive Phase 1/1b trial data for soquelitinib in T cell lymphoma, showing significant anti-tumor activity. Corvus Pharmaceuticals, Inc. announced new findings ...

Reports as of December 31, Corvus had cash, cash equivalents and marketable securities of $52.M as compared to $27.1M as of December 31, 2023.

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in MayInitial Results From First Two ...

Corvus Pharmaceuticals Inc (CRVS) reports significant progress in clinical trials and a strong cash position, despite increased net losses and R&D expenses.

SOUTH SAN FRANCISCO – Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company with a market capitalization of $284 million, today shared additional data from its Phase ...

SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that additional data from ...

The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of patients,” ...